



Ohio Board of Nursing

www.nursing.ohio.gov

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

Committee on Prescriptive Governance (CPG) DRAFT MINUTES May 16, 2016

Members Attending: Jeanne E. Bauer, MSN, CNM, Chair; Columbus
Anne Sapienze-Crawford, RN, MSN, CNP; Findlay
Dennis Helmuth, MD, PhD; Wooster
Richard Bakker, MD, PhD; Columbus
Curtis Passafume, Jr. MBA, RPh; Columbus

Members Absent: Nancy Fellows, RN; Willoughby Hills
Anita Steinbergh, DO; Columbus
Catherine Clark, DO; Clayton
Pamela Bolton, RN, MS, CCNS; Harrison

Board Staff Attending: Lisa Emrich, Program Manager
Anita DiPasquale, JD; Staff Attorney
Jennifer Burgess, Administrative Professional

Guests Attending: Linda Huang, Ohio Health
Sherri Sievers, Cincinnati Children's Hospital
Kim Kombriwck, Cincinnati Children's Hospital
Carol Cairns, OAAPN / Blanchard Valley Hospital
Erin Keels, Nationwide Children's Hospital

Call to Order

Jeanne Bauer, Chair, called the meeting to order at 10:26 a.m., with a quorum present. The CPG members introduced themselves.

Legislative Update

Tom Dilling provided the following information:

- Betsy Houchen, Executive Director, provided testimony to the General Assembly Sunset Review Committee recommending that the CPG continue. CPG members were provided a copy of the testimony.
- HB 216, the APRN bill, is currently in its eight revised version, and T. Dilling is awaiting communications regarding its content, which he understands includes language that will

further change the Formulary to an exclusionary format and change the manner in which the CPG will address new drugs.

- T. Dilling discussed amendments to Chapter 4723-9, OAC, reflecting changes consistent with the Governor's Cabinet Opiate Action Team (GCOAT) recommendations.

Approval of January 11, 2016 Meeting Minutes

The Committee of Prescriptive Governance approved the January 11, 2016 minutes by consensus.

Drug Facts & Comparisons®

Lisa Emrich discussed CPG members having direct access to the online drug reference and asked for feedback regarding the number of concurrent CPG member accesses that would be needed. It was agreed that three would be sufficient.

Jeanne Bauer stated that she had been asked whether a drug reference other than Facts & Comparisons could be used by the CPG, as practitioners said they have limited access to it and that it is not compatible with some electronic medical records. L. Emrich stated when the CPG was initially convened, it elected to use Drug Facts & Comparisons because it was unbiased, and the organization of the drugs and categories was quite clear. It would be up to the CPG to determine whether it should use another resource. Should the CPG decide to use a different drug reference, the decision would impact the Formulary, as it is organized consistent with Drug Facts & Comparisons. Dennis Helmuth stated that, since HB 216 will likely impact the Formulary and how it is organized that this is not a good time for the CPG to change drug references. The CPG members agreed.

4723-9-02 & 4723-9-11, OAC

J. Bauer referred to the draft amended rules in the meeting packet. The amendments are consistent with GCOAT recommendations. J. Bauer asked for the CPG's review and recommendations regarding the amendments. The CPG agreed by general consensus to recommend the proposed amendments.

Review of New Drugs: Please see the May 2016 Formulary Updates for CPG determinations concerning new FDA approved drugs.

Review of New Drug Indications/Black Box Warnings: Please see the May 2016 Formulary Updates for CPG determinations concerning drugs with new FDA indications and black box warnings.

Formulary Revision Requests: Please see the May 2016 Formulary Updates for CPG determinations concerning Formulary Revision Requests. The individuals submitting the requests were called but were not in attendance. The requests submitted for buprenorphine buccal film and deoxycholic acid were discussed by the CPG agreed by general consensus that the prescribing designation for these two drugs will not be changed at this time.

Review of Prescribing Designations

The CPG reviewed the drugs within the Formulary sections *Endocrine and Metabolic Agents* that are currently designated as "may not prescribe" and "in accordance with the SCA." The CPG determined that no changes would be made to these drugs at this time. Please see the May 2016 Formulary Updates for the drugs reviewed.

Meeting Dates for 2016

October 17, 2016

Adjournment

Having no further business the meeting adjourned at approximately 11:16 a.m.

DRAFT